{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:18:49Z","timestamp":1789496329166,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hebei medical science research project plan","award":["20220384"],"award-info":[{"award-number":["20220384"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:p>\n                    Thyroid nodule (TN) prevalence is rising globally, with particularly high rates among patients with type 2 diabetes mellitus, where insulin resistance and hyperinsulinemia may promote nodule formation via the thyroid-stimulating hormone (TSH)\/insulin-like growth factor-1 axis. Metformin, the standard first-line therapy for T2DM, may exert additional effects on thyroid structure beyond glycemic control. This single-center retrospective cohort study enrolled 80 patients with T2DM and benign TNs, assigned to a metformin group (n\u2005=\u200540) or control group (n\u2005=\u200540), and followed for 12 months. Changes in TSH and nodule volume were assessed using multivariable regression, propensity score matching, and sensitivity and subgroup analyses to address confounding. After 12 months, metformin treatment was associated with a significant reduction in TSH (adjusted \u03b2\u2005=\u2005\u22120.32, 95% confidence interval: \u22120.57 to \u22120.06,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.017) and nodule volume (adjusted \u03b2\u2005=\u2005\u22128.5, 95% confidence interval: \u221215.9 to \u22121.1,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.024). These effects were consistent in sensitivity analyses, with stronger associations observed in men, patients with body mass index\u2005&lt;\u200528\u2009kg\/m\u00b2, and those with glycated hemoglobin\u2005&lt;\u20058%. In conclusion, metformin significantly lowers TSH levels and reduces nodule size in T2DM patients with benign TNs, supporting its potential clinical utility. Confirmation through large, multicenter, long-term prospective trials is warranted.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047392","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:00:25Z","timestamp":1770404425000},"page":"e47392","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical retrospective analysis of metformin on TSH levels and nodule volume in patients with type 2 diabetes mellitus combined with thyroid nodules"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7353-6778","authenticated-orcid":false,"given":"Zheng","family":"Ma","sequence":"first","affiliation":[{"name":"Pharmaceutical Department, Cangzhou Central Hospital, Cangzhou, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Endocrine Diabetes Department, Cangzhou Central Hospital, Cangzhou, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Cangzhou Central Hospital, Cangzhou, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"1029926","DOI":"10.3389\/fonc.2022.1029926","article-title":"Mapping global epidemiology of thyroid nodules among general population: a systematic review and meta-analysis.","volume":"12","author":"Mu","year":"2022","journal-title":"Front Oncol"},{"key":"R2-20260915","first-page":"298","article-title":"Thyroid nodules: advances in evaluation and management.","volume":"102","author":"Kant","year":"2020","journal-title":"Am Fam Physician"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"1113977","DOI":"10.3389\/fendo.2023.1113977","article-title":"Thyroid nodules: global, economic, and personal burdens.","volume":"14","author":"Uppal","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"730279","DOI":"10.3389\/fendo.2021.730279","article-title":"Correlation between thyroid nodules and metabolic syndrome: a systematic review and meta-analysis.","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"661160","DOI":"10.3389\/fendo.2021.661160","article-title":"The relationship between thyroid function and metabolic syndrome and its components: a cross-sectional study in a Chinese population.","volume":"12","author":"He","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"1444279","DOI":"10.3389\/fendo.2024.1444279","article-title":"Predictive value of IGF-1\/IGFBP-3 ratio for thyroid nodules in type 2 diabetic mellitus.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/thy.2017.0707","article-title":"Role of metformin in the treatment of patients with thyroid nodules and insulin resistance: a systematic review and meta-analysis.","volume":"29","author":"He","year":"2019","journal-title":"Thyroid"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"18757","DOI":"10.1038\/s41598-023-43266-9","article-title":"The effect of metformin therapy on serum thyrotropin and free thyroxine concentrations in patients with type 2 diabetes: a meta-analysis.","volume":"13","author":"Amirabadizadeh","year":"2023","journal-title":"Sci Rep"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/biom12040574","article-title":"Metformin in differentiated thyroid cancer: molecular pathways and its clinical implications.","volume":"12","author":"Garc\u00eda-S\u00e1enz","year":"2022","journal-title":"Biomolecules"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s40001-023-01287-0","article-title":"Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses.","volume":"28","author":"Li","year":"2023","journal-title":"Eur J Med Res"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"e0271038","DOI":"10.1371\/journal.pone.0271038","article-title":"Metformin and thyroid carcinoma incidence and prognosis: a systematic review and meta-analysis.","volume":"17","author":"Wang","year":"2022","journal-title":"PLoS One"},{"key":"R12-20260915","first-page":"6180","article-title":"Metformin ameliorates insulin resistance, thyroid nodules and thyroid function.","volume":"15","author":"Ji","year":"2023","journal-title":"Am J Transl Res"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fendo.2018.00494","article-title":"Efficacy of metformin for benign thyroid nodules in subjects with insulin resistance: a systematic review and meta-analysis.","volume":"9","author":"Sui","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R14-20260915","first-page":"1019","article-title":"Effect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: a randomized placebo-controlled clinical trial.","volume":"19","author":"Karimifar","year":"2014","journal-title":"J Res Med Sci"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"3145234","DOI":"10.1155\/2017\/3145234","article-title":"The clinical values of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels in blood and thyroid nodules.","volume":"2017","author":"Altas","year":"2017","journal-title":"Int J Endocrinol"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"622262","DOI":"10.3389\/fphar.2021.622262","article-title":"Metformin: a novel weapon against inflammation.","volume":"12","author":"Bai","year":"2021","journal-title":"Front Pharmacol"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1089\/thy.2017.0550","article-title":"Protective effect of metformin against thyroid cancer development: a population-based study in Korea.","volume":"28","author":"Cho","year":"2018","journal-title":"Thyroid"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/dom.15292","article-title":"Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a population-based cohort study.","volume":"26","author":"Bea","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1007\/s13277-015-3315-4","article-title":"Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.","volume":"36","author":"Han","year":"2015","journal-title":"Tumour Biol"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"2530697","DOI":"10.1080\/07853890.2025.2530697","article-title":"Insulin resistance factors associated with differentiated thyroid carcinoma and malignant cytology: serum thyroxine as an associated factor.","volume":"57","author":"Celescuekci","year":"2025","journal-title":"Ann Med"},{"key":"R21-20260915","first-page":"2333392818775517","article-title":"The impact of metabolic syndrome on increased risk of thyroid nodules and size.","volume":"5","author":"Bener","year":"2018","journal-title":"Health Serv Res Manag Epidemiol"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11596-019-2076-5","article-title":"Thyroid nodules in type 2 diabetes mellitus.","volume":"39","author":"Zhang","year":"2019","journal-title":"Curr Med Sci"},{"key":"R23-20260915","first-page":"1292","article-title":"Thyroid nodules and obesity.","volume":"13","author":"Demetriou","year":"2023","journal-title":"Life (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:01:03Z","timestamp":1789495263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047392","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2025-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}